2015 Featured Speakers

  • Kees BeenCEO & President Lysosomal Therapeutics

  • Alastair BrownHead of Pharmacology Heptares Therapeutics

  • Craig FerrisDirector, Centre for Neurotranslational Imaging Northeastern University

  • Paul McGonigleHead, Drug Discovery & Development Program Drexel University

Improve your CNS Drug Discovery Success by Enhancing your Preclinical Modeling and Biomarker Development Strategies

Following the success of previous meetings, this year we have researched with the CNS community to bring you a meeting which will focus on providing you with the key information to improve the predictive validity of preclinical models and biomarkers to ensure drug safety and efficacy before these drugs are moved to trials. 

Designed to build on the collaboration of previous years and drive the forward movement for the industry, the leading drug developers will be here, sharing their honest insights and experiences. Attend and you will discover new ways to progress your pipeline and tap into the huge commercial opportunity CNS diseases represent.

Attendees will meet with commercial and academic leaders to inspire new ideas and strategies to help minimize clinical attrition, maximize pipeline potential and see a return on investments made in the CNS field.

Attendees will learn how to:

  • Increase the predictive value of animal models for more cost effective approaches
  • Improve the way you measure drug efficacy by validating new biomarkers
  • Optimize drug delivery and exposure in the brain with novel techniques
  • Identify novel models that can be used in your preclinical research to prove drug safety and efficacy
  • Implement imaging biomarkers in to your research for functional read outs

Discover the technologies and techniques that are proving beneficial to drug development and avoid the approaches that have historically led to failure. 

 

“The talks were high quality and the interaction among the participants was excellent”

Genentech